AFT Pharmaceuticals achieves record revenue, eyes $300m target

AFT Pharmaceuticals (NZX:AFT) has announced record revenue for the financial year ending March 31, 2025, with sales exceeding $200 million and setting its sights on a $300 million revenue target by the end of 2027. Full year operating revenue increased by 6% to NZD 208.0 million, driven by an 11% increase in product sales and royalties across all territories. The company reported EBITDA of NZD 20.9 million, down 20%, and operating profit of NZD 17.6 million, a 27% decrease, aligning with previous guidance. Despite headwinds like customer destocking and a doctor's strike in South Korea, AFT saw strong Australian sales growth of 17%. Asia revenue rose by 4% to NZD 11.1 million, with second-half sales up 50% compared to the first half of the year. Consistent with its positive outlook, AFT has declared an increased dividend of 1.8 cents per share. The company is focused on expanding its reach and R&D pipeline and anticipates operating profit for FY 26 to range from NZD 20 million to NZD 24 million.